What does participation involve?

What does the study involve for MDD & Control participants?
After an initial telephone screening process the patient will undergo the following at prior to and 8 weeks after the commencement of medication:

• Clinical Psychological Assessment
• Blood (12mL) and urine collection 
• Neuropsychological Testing 
• Electroencephalography 
• MRI scan data.

Patients will continue to be monitored for changes in medication, symptoms and medication side-effects through-out the study by trained staff. Patients will be reimbursed for their time, inconvenience and reasonable travel expenses.

Participation for MDD participants only;
Participation for MDD participants will additionally include treatment with one of three standard (/commonly prescribed) antidepressant medications. These antidepressants are Sertraline, Escitalopram and Venlafaxine.

What are the treatment options?
Individuals suffering from depression (MDD participants) will be treated with one of three commonly prescribed antidepressant medications. These are Sertraline, Escitalopram, and Venlafaxine . These participants will be allocated to one of these groups at random but they will be fully aware and informed about the antidepressant treatment they are given. Further, all treatments will be monitored either by their own GP or a GP involved in iSPOT-D.

Clickfor Participation Criteria